News
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Reports First Quarter 2026 Financials
Jaguar Health, Inc. reports significant revenue increase driven by license agreements for Mytesi® and Canalevia®-CA1, focuses on crofelemer development for rare intestinal indications. Upcoming presentations at ESPGHAN Meeting. Info on investor webcast and CEO's virtual presentation -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer
First MVID patient enters active treatment extension phase with liquid crofelemer as adjunctive therapy. Jaguar Health focuses on rare pediatric disease treatment -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule
Jaguar Health, Inc. receives extension from Nasdaq Hearings Panel for compliance with Listing Rules. Company regained compliance with Publicly Held Shares Requirement -
